Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 3/10

vs
industry
vs
history
Cash-to-Debt 0.03
NAS:BIOS's Cash-to-Debt is ranked lower than
90% of the 259 Companies
in the Global Medical Care industry.

( Industry Median: 0.48 vs. NAS:BIOS: 0.03 )
Ranked among companies with meaningful Cash-to-Debt only.
NAS:BIOS' s Cash-to-Debt Range Over the Past 10 Years
Min: 0  Med: 0.53 Max: No Debt
Current: 0.03
Equity-to-Asset -0.08
NAS:BIOS's Equity-to-Asset is ranked lower than
95% of the 255 Companies
in the Global Medical Care industry.

( Industry Median: 0.48 vs. NAS:BIOS: -0.08 )
Ranked among companies with meaningful Equity-to-Asset only.
NAS:BIOS' s Equity-to-Asset Range Over the Past 10 Years
Min: -0.18  Med: 0.42 Max: 0.75
Current: -0.08
-0.18
0.75
Interest Coverage 0.19
NAS:BIOS's Interest Coverage is ranked lower than
99% of the 216 Companies
in the Global Medical Care industry.

( Industry Median: 8.41 vs. NAS:BIOS: 0.19 )
Ranked among companies with meaningful Interest Coverage only.
NAS:BIOS' s Interest Coverage Range Over the Past 10 Years
Min: 0.19  Med: 0.63 Max: 8.06
Current: 0.19
0.19
8.06
Piotroski F-Score: 5
Altman Z-Score: 0.37
Beneish M-Score: -1.74
WACC vs ROIC
7.76%
2.75%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating Margin % 0.68
NAS:BIOS's Operating Margin % is ranked lower than
76% of the 260 Companies
in the Global Medical Care industry.

( Industry Median: 7.34 vs. NAS:BIOS: 0.68 )
Ranked among companies with meaningful Operating Margin % only.
NAS:BIOS' s Operating Margin % Range Over the Past 10 Years
Min: -7.33  Med: 0.76 Max: 4.61
Current: 0.68
-7.33
4.61
Net Margin % -5.62
NAS:BIOS's Net Margin % is ranked lower than
83% of the 261 Companies
in the Global Medical Care industry.

( Industry Median: 4.40 vs. NAS:BIOS: -5.62 )
Ranked among companies with meaningful Net Margin % only.
NAS:BIOS' s Net Margin % Range Over the Past 10 Years
Min: -30.51  Med: -4.86 Max: 10.9
Current: -5.62
-30.51
10.9
ROA % -9.01
NAS:BIOS's ROA % is ranked lower than
87% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 3.85 vs. NAS:BIOS: -9.01 )
Ranked among companies with meaningful ROA % only.
NAS:BIOS' s ROA % Range Over the Past 10 Years
Min: -44.23  Med: -8.06 Max: 20.26
Current: -9.01
-44.23
20.26
ROC (Joel Greenblatt) % 7.06
NAS:BIOS's ROC (Joel Greenblatt) % is ranked lower than
69% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 16.07 vs. NAS:BIOS: 7.06 )
Ranked among companies with meaningful ROC (Joel Greenblatt) % only.
NAS:BIOS' s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -76.36  Med: 4.07 Max: 17.14
Current: 7.06
-76.36
17.14
3-Year Revenue Growth Rate -2.60
NAS:BIOS's 3-Year Revenue Growth Rate is ranked lower than
80% of the 193 Companies
in the Global Medical Care industry.

( Industry Median: 8.00 vs. NAS:BIOS: -2.60 )
Ranked among companies with meaningful 3-Year Revenue Growth Rate only.
NAS:BIOS' s 3-Year Revenue Growth Rate Range Over the Past 10 Years
Min: -35  Med: 4.5 Max: 15.9
Current: -2.6
-35
15.9
3-Year EPS without NRI Growth Rate -25.40
NAS:BIOS's 3-Year EPS without NRI Growth Rate is ranked lower than
85% of the 145 Companies
in the Global Medical Care industry.

( Industry Median: 7.50 vs. NAS:BIOS: -25.40 )
Ranked among companies with meaningful 3-Year EPS without NRI Growth Rate only.
NAS:BIOS' s 3-Year EPS without NRI Growth Rate Range Over the Past 10 Years
Min: -82.7  Med: -21.5 Max: 502.8
Current: -25.4
-82.7
502.8
GuruFocus has detected 7 Warning Signs with BioScrip Inc $NAS:BIOS.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» NAS:BIOS's 30-Y Financials

Financials (Next Earnings Date: 2017-08-08)


Revenue & Net Income
Cash & Debt
Operating Cash Flow & Free Cash Flow
Operating Cash Flow & Net Income

» Details

Guru Trades

Q2 2016

BIOS Guru Trades in Q2 2016

Paul Tudor Jones 247,500 sh (New)
Diamond Hill Capital 5,317,224 sh (+48.99%)
Mario Gabelli 904,402 sh (+7.75%)
Pioneer Investments 280,320 sh (unchged)
» More
Q3 2016

BIOS Guru Trades in Q3 2016

Pioneer Investments 280,320 sh (unchged)
Paul Tudor Jones Sold Out
Diamond Hill Capital 5,306,619 sh (-0.20%)
Mario Gabelli 875,102 sh (-3.24%)
» More
Q4 2016

BIOS Guru Trades in Q4 2016

Mario Gabelli 1,157,601 sh (+32.28%)
Pioneer Investments 280,320 sh (unchged)
Diamond Hill Capital 5,305,400 sh (-0.02%)
» More
Q1 2017

BIOS Guru Trades in Q1 2017

Pioneer Investments 280,320 sh (unchged)
Diamond Hill Capital 5,151,236 sh (-2.91%)
Mario Gabelli 926,551 sh (-19.96%)
» More
» Details

Insider Trades

Latest Guru Trades with NAS:BIOS

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Health Care Providers » Medical Care    NAICS: 621610    SIC: 8082
Compare:NAS:ADUS, NYSE:AAC, AMEX:HLTH, NYSE:QHC, NAS:CATS, OTCPK:AMEH, NAS:JYNT, OTCPK:CCEL, OTCPK:FCHS, OTCPK:ADPTQ, OTCPK:BICX, OTCPK:MIHI, AMEX:AMS, TSXV:CXV, OTCPK:HPHW, AMEX:SSY, OTCPK:PFHO, TSXV:AHI, NAS:PRSC, OTCPK:WNDM » details
Traded in other countries:MM6.Germany,
Headquarter Location:USA
BioScrip Inc provides home infusion & other home healthcare services to patients, physicians, hospitals, healthcare payors & pharmaceutical manufacturers to provide clinical management solutions & delivers cost-effective access to medications.

BioScrip Inc, formerly known as MIM Corporation, was incorporated in Delaware in 1996. The Company provides home infusion and other home healthcare services to patients, physicians, hospitals, healthcare payors and pharmaceutical manufacturers to provide clinical management solutions and delivers cost-effective access to prescription medications and home health services. Its services are provided in coordination with, and under the direction of the patient's physicians. The sales and marketing efforts are focused on payors, healthcare systems and physician prescribers and are driven by dedicated managed care and physician sales teams as well as home health care consultants. PBM Services has over 100 relationships with PBM clients, including Medicaid MCOs, employers, TPAs, workers compensation providers and discount card marketers. The Company undertakes direct sales methods to promote the discount card program and add new marketing organizations. The Company owns trademarks, trade names and service marks including BioScrip, BioScrip Infusion Services, BioScrip Medical Supply Services, BioScrip PBM Services, BioScrip Pharmacy Services, Applied Health Care, CarePoint Partners, Critical Homecare Solutions, Deaconess HomeCare, Deaconess Hospice, among others. The Company's competitors within the home infusion market include Walgreen Co., including OptionCare and Critical Care Systems; CVS Caremark Corp., through its recent acquisition of the Coram infusion business; Express Scripts Holding Company through its subsidiary Accredo Health Group; and various regional and local providers of alternate site healthcare services such as hospitals, local home health agencies, and other local providers. In Home Health Services, the Company competes with Gentiva Health Services, Inc., Almost Family, Inc., Amedisys, Inc., LHC Group, Inc., among others. In PBM and Discount Card Services, the competitors include Express Scripts, Inc., Catamaran Corp., and CVS/Caremark Corp.

Top Ranked Articles about BioScrip Inc

BioScrip To Host Second Quarter Results Call
BioScrip Provides Update on UnitedHealthcare Contract
BioScrip to Present at the Jefferies 2017 Global Healthcare Conference
BioScrip Announces CFO Transition
BioScrip To Host First Quarter 2017 Results Call
BioScrip Announces Meeting with Investors

Company Expects Improved Profitability Following Termination of Agreement with UnitedHealthcare
DENVER, March 27, 2017 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), a leading national provider of infusion and home care management solutions, today announced members of management will be meeting with analysts and investors in New York City and Boston, on March 28-March 29, 2017.  In conjunction with these meetings, the Company is publishing an updated investor presentation to the investor relations section of the Company’s website.In the presentation, management reiterates its 2017 adjusted EBITDA forecast of $45.0 million to $55.0 million.  First quarter 2017 adjusted EBITDA is anticipated to be lower year over year reflecting the rollout by the Company of Cures Act legislation mitigation measures, which were fully implemented by late January 2017.  The reiteration of the company’s adjusted EBITDA outlook for the year reflects the recent termination by the Company of its contract with UnitedHealthcare, which will become effective September 30, 2017.  Although UnitedHealthcare was the Company’s largest payor, accounting for 24% of 2016 revenue, the contract was not profitable and its termination is expected to have a positive impact on adjusted EBITDA outlook going forward.“We continue to leverage our CORE initiative to accelerate the growth of our profitable business segments and improve operational efficiencies throughout the organization,” said Daniel E. Greenleaf, President and Chief Executive Officer. “It is difficult to end a relationship with a business partner, but in this circumstance, we believe our business needs do not align. The exit of this contract is consistent with our CORE initiative and better positions BioScrip for improved operating results going forward.” About BioScripBioScrip, Inc. is a leading national provider of infusion and home care management solutions. BioScrip partners with physicians, hospital systems, skilled nursing facilities, healthcare payors, and pharmaceutical manufacturers to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves.Forward-Looking Statements - Safe HarborThis press release includes statements that may constitute "forward-looking statements,” that involve substantial risks and uncertainties, including the statements regarding 2017 guidance, the anticipated effects of the UnitedHealthcare contract termination and other statements regarding the Company’s plans and strategies. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the fact that they do not relate strictly to historical or current facts. In some cases, forward-looking statements can be identified by words such as "may," "should," "could," "anticipate," "estimate," "expect," "project," "outlook," "aim," "intend," "plan," "believe," "predict," "potential," "continue" or comparable terms. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Important factors that could cause or contribute to such differences include but are not limited to risks associated with: the Company's ability to integrate the acquisition of Home Solutions, the Company's ability to grow its core Infusion revenues, the Company's ability to continue to experience positive results from its financial improvement plan to reduce operating costs; the Company’s ability to comply with the covenants in its debt agreements; the UnitedHealthcare contract termination, including potential accounting charges and impacts on other contract provisions and their associated revenue; the success of the Company’s initiatives to mitigate the impact of the Cures Act on its business; reductions in federal, state and commercial reimbursement for the Company's products and services; increased government regulation related to the health care and insurance industries; as well as the risks described in the Company's periodic filings with the Securities and Exchange Commission. The Company does not undertake any duty to update these forward-looking statements after the date hereof, even though the Company's situation may change in the future. All of the forward-looking statements herein are qualified by these cautionary statements.Note Regarding Use of Non-GAAP Financial MeasuresThis press release includes projected adjusted EBITDA, which is a non-GAAP financial measure. Adjusted EBITDA is not a measurement of financial performance under GAAP and should not be used in isolation or as a substitute or alternative to net income, operating income or any other performance measure derived in accordance with GAAP, or as a substitute or alternative to cash flow from operating activities or a measure of the Company’s liquidity. In addition, the Company's definition of adjusted EBITDA may not be comparable to similarly titled non-GAAP financial measures reported by other companies. Adjusted EBITDA, as defined by the Company, represents net income before net interest expense, income tax expense, depreciation and amortization, impairment of goodwill, stock-based compensation expense, and restructuring, integration and other expenses. As part of restructuring, the Company may incur significant charges such as the write down of certain long−lived assets, temporary redundant expenses, retraining expenses, potential cash bonus payments and potential accelerated payments or terminated costs for certain of its contractual obligations. Management believes that adjusted EBITDA provides useful supplemental information regarding the performance of BioScrip’s business operations and facilitates comparisons to the Company’s historical operating results. The Company’s March 3, 2017 earnings release provides a reconciliation of projected adjusted EBITDA to expected results.
For Further Information:

Investor Contacts
Jeffrey M. Kreger
Chief Financial Officer
(720) 697-5200
[email protected]

David Clair
ICR, Inc.
(646) 277-1266
[email protected]

Read more...
BioScrip Raises Approximately $5 million in Private Placement of Common Stock

DENVER, March 02, 2017 (GLOBE NEWSWIRE) -- BioScrip, Inc. (NASDAQ:BIOS) ("BioScrip" or the "Company"), a leading national provider of infusion and home care management solutions, today announced that it entered into a Stock Purchase Agreement on March 1, 2017, for the sale of an aggregate of 3,300,000 shares of its common stock (the “Shares”) for aggregate gross proceeds of $5,070,780 in a private placement transaction (the “Private Placement”) to Venor Capital Management LP and affiliated funds (the “Purchasers”). The purchase price for each Share was $1.5366, which was negotiated between the Company and the Purchasers based on the volume-weighted average price of the Company’s common stock on The NASDAQ Global Market on March 1, 2017. 
Proceeds from the Private Placement will be used for working capital and general corporate purposes. The Private Placement is exempt from the registration requirements of the Securities Act of 1933, as amended (the “Securities Act”) pursuant to the exemption for transactions by an issuer not involving any public offering under Section 4(a)(2) of the Securities Act and Regulation D under the Securities Act. The securities sold and issued in the Private Placement will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration with the SEC or an applicable exemption from the registration requirements. In connection with the Private Placement, the Company entered into a Registration Rights Agreement (the “Registration Rights Agreement”) with the Purchasers. Pursuant to the Registration Rights Agreement, the Company agreed to prepare and file a registration statement with the Securities and Exchange Commission (the “SEC”) within ten (10) days of the date it files its annual report on Form 10-K for the fiscal year ended December 31, 2016, for purposes of registering the resale of the Shares and any shares of common stock issued as a dividend or other distribution with respect to the Shares. The Company also agreed, among other things, to indemnify the selling holders under the registration statement from certain liabilities and to pay all fees and expenses (excluding underwriting discounts and selling commissions and legal fees) incident to the Company’s obligations under the Registration Rights Agreement. Dechert LLP is serving as legal advisor to BioScrip, and Akin Gump Strauss Hauer & Feld LLP is serving as legal advisor to the Purchasers.
  
About BioScrip, Inc.
BioScrip, Inc. is a leading national provider of infusion and home care management solutions. BioScrip partners with physicians, hospital systems, skilled nursing facilities, healthcare payors, and pharmaceutical manufacturers to provide patients access to post-acute care services. BioScrip operates with a commitment to bring customer-focused pharmacy and related healthcare infusion therapy services into the home or alternate-site setting. By collaborating with the full spectrum of healthcare professionals and the patient, BioScrip provides cost-effective care that is driven by clinical excellence, customer service, and values that promote positive outcomes and an enhanced quality of life for those it serves. Forward-Looking Statements – Safe Harbor This press release includes statements that may constitute "forward-looking statements,” that involve substantial risks and uncertainties. These statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You can identify these statements by the fact that they do not relate strictly to historical or current facts. In some cases, forward-looking statements can be identified by words such as "may," "should," "could," "anticipate," "estimate," "expect," "project," "outlook," "aim," "intend," "plan," "believe," "predict," "potential," "continue" or comparable terms. Because such statements inherently involve risks and uncertainties, actual future results may differ materially from those expressed or implied by such forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, and that actual results may differ materially from those in the forward-looking statements as a result of various factors. Important factors that could cause or contribute to such differences include but are not limited to risks associated with: the Company’s ability to complete the Private Placement on acceptable terms or at all, the Company's ability to integrate the acquisition of Home Solutions, the Company's ability to grow its core Infusion revenues, the Company's ability to continue to experience positive results from its financial improvement plan to reduce operating costs; the Company’s ability to comply with the covenants in its debt agreements; the success of the Company’s initiatives to mitigate the impact of the Cures Act on its business; reductions in federal, state and commercial reimbursement for the Company's products and services; increased government regulation related to the health care and insurance industries; as well as the risks described in the Company's periodic filings with the Securities and Exchange Commission. The Company does not undertake any duty to update these forward-looking statements after the date hereof, even though the Company's situation may change in the future. All of the forward-looking statements herein are qualified by these cautionary statements.
For Further Information:

Investor Contacts

Jeffrey M. Kreger
Chief Financial Officer
(720) 697-5200
[email protected]

David Clair
ICR, Inc.
(646) 277-1266
[email protected]

Read more...

Ratios

vs
industry
vs
history
PS Ratio 0.32
BIOS's PS Ratio is ranked higher than
93% of the 253 Companies
in the Global Medical Care industry.

( Industry Median: 1.69 vs. BIOS: 0.32 )
Ranked among companies with meaningful PS Ratio only.
BIOS' s PS Ratio Range Over the Past 10 Years
Min: 0.04  Med: 0.23 Max: 1.89
Current: 0.32
0.04
1.89
EV-to-EBIT 130.70
BIOS's EV-to-EBIT is ranked lower than
96% of the 208 Companies
in the Global Medical Care industry.

( Industry Median: 20.05 vs. BIOS: 130.70 )
Ranked among companies with meaningful EV-to-EBIT only.
BIOS' s EV-to-EBIT Range Over the Past 10 Years
Min: -233  Med: 3.2 Max: 9138.1
Current: 130.7
-233
9138.1
EV-to-EBITDA 26.86
BIOS's EV-to-EBITDA is ranked lower than
80% of the 221 Companies
in the Global Medical Care industry.

( Industry Median: 15.41 vs. BIOS: 26.86 )
Ranked among companies with meaningful EV-to-EBITDA only.
BIOS' s EV-to-EBITDA Range Over the Past 10 Years
Min: -135.9  Med: 14.7 Max: 121
Current: 26.86
-135.9
121
Current Ratio 1.45
BIOS's Current Ratio is ranked higher than
55% of the 260 Companies
in the Global Medical Care industry.

( Industry Median: 1.32 vs. BIOS: 1.45 )
Ranked among companies with meaningful Current Ratio only.
BIOS' s Current Ratio Range Over the Past 10 Years
Min: 0.86  Med: 1.35 Max: 2.76
Current: 1.45
0.86
2.76
Quick Ratio 1.20
BIOS's Quick Ratio is ranked lower than
51% of the 260 Companies
in the Global Medical Care industry.

( Industry Median: 1.25 vs. BIOS: 1.20 )
Ranked among companies with meaningful Quick Ratio only.
BIOS' s Quick Ratio Range Over the Past 10 Years
Min: 0.79  Med: 1.16 Max: 2.5
Current: 1.2
0.79
2.5
Days Inventory 18.21
BIOS's Days Inventory is ranked lower than
53% of the 198 Companies
in the Global Medical Care industry.

( Industry Median: 15.65 vs. BIOS: 18.21 )
Ranked among companies with meaningful Days Inventory only.
BIOS' s Days Inventory Range Over the Past 10 Years
Min: 11.42  Med: 20.93 Max: 80.5
Current: 18.21
11.42
80.5
Days Sales Outstanding 43.67
BIOS's Days Sales Outstanding is ranked lower than
53% of the 215 Companies
in the Global Medical Care industry.

( Industry Median: 40.40 vs. BIOS: 43.67 )
Ranked among companies with meaningful Days Sales Outstanding only.
BIOS' s Days Sales Outstanding Range Over the Past 10 Years
Min: 36.18  Med: 47.85 Max: 178.08
Current: 43.67
36.18
178.08
Days Payable 26.73
BIOS's Days Payable is ranked lower than
68% of the 160 Companies
in the Global Medical Care industry.

( Industry Median: 44.51 vs. BIOS: 26.73 )
Ranked among companies with meaningful Days Payable only.
BIOS' s Days Payable Range Over the Past 10 Years
Min: 19.73  Med: 32.58 Max: 109.18
Current: 26.73
19.73
109.18

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -20.00
BIOS's 3-Year Average Share Buyback Ratio is ranked lower than
84% of the 141 Companies
in the Global Medical Care industry.

( Industry Median: -2.20 vs. BIOS: -20.00 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
BIOS' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -20  Med: -10.15 Max: -0.5
Current: -20
-20
-0.5

Valuation & Return

vs
industry
vs
history
Price-to-Median-PS-Value 1.42
BIOS's Price-to-Median-PS-Value is ranked lower than
67% of the 226 Companies
in the Global Medical Care industry.

( Industry Median: 1.10 vs. BIOS: 1.42 )
Ranked among companies with meaningful Price-to-Median-PS-Value only.
BIOS' s Price-to-Median-PS-Value Range Over the Past 10 Years
Min: 0.23  Med: 1 Max: 6.65
Current: 1.42
0.23
6.65
Earnings Yield (Greenblatt) % 0.77
BIOS's Earnings Yield (Greenblatt) % is ranked lower than
76% of the 263 Companies
in the Global Medical Care industry.

( Industry Median: 3.84 vs. BIOS: 0.77 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) % only.
BIOS' s Earnings Yield (Greenblatt) % Range Over the Past 10 Years
Min: -84.9  Med: 0.8 Max: 47.3
Current: 0.77
-84.9
47.3
Forward Rate of Return (Yacktman) % -13.97
BIOS's Forward Rate of Return (Yacktman) % is ranked lower than
88% of the 127 Companies
in the Global Medical Care industry.

( Industry Median: 10.98 vs. BIOS: -13.97 )
Ranked among companies with meaningful Forward Rate of Return (Yacktman) % only.
BIOS' s Forward Rate of Return (Yacktman) % Range Over the Past 10 Years
Min: -16.4  Med: -1.7 Max: 5.9
Current: -13.97
-16.4
5.9

More Statistics

Revenue (TTM) (Mil) $914.94
EPS (TTM) $ -0.56
Beta0.71
Short Percentage of Float17.79%
52-Week Range $0.98 - 3.43
Shares Outstanding (Mil)120.98

Analyst Estimate

Dec17 Dec18 Dec19
Revenue (Mil $) 866 765 804
EPS ($) -0.30 -0.18 -0.02
EPS without NRI ($) -0.30 -0.18 -0.02
EPS Growth Rate
(Future 3Y To 5Y Estimate)
12.00%
Dividends per Share ($)
» More Articles for BIOS

Headlines

Articles On GuruFocus.com
BioScrip To Host Second Quarter Results Call Jul 17 2017 
BioScrip Provides Update on UnitedHealthcare Contract May 30 2017 
BioScrip to Present at the Jefferies 2017 Global Healthcare Conference May 24 2017 
BioScrip Announces CFO Transition Apr 20 2017 
BioScrip To Host First Quarter 2017 Results Call Apr 17 2017 
BioScrip Announces Meeting with Investors Mar 27 2017 
BioScrip Raises Approximately $5 million in Private Placement of Common Stock Mar 02 2017 
5-year lows: Elizabeth Arden Inc, Systemax Inc, BioScrip Inc, and Thompson Creek Metals Co Inc. May 26 2015 
5-year lows: Resource Capital Corp, Dynex Capital Inc, BioScrip Inc, and Kemet Corp. May 10 2015 
Two Gurus Hold Stakes in Embattled BioScrip Apr 07 2015 

More From Other Websites
BioScrip To Host Second Quarter Results Call Jul 17 2017
Zacks.com featured highlights: Ardelyx, Novavax, BioScrip, Layne Christensen and Resonant Jul 10 2017
5 Breakout Stocks Offering Phenomenal Returns Jul 07 2017
BioScrip (BIOS) Strong on Infusion, Reimbursement a Drag Jun 30 2017
BioScrip Announces New Senior Note Facilities Jun 29 2017
Edited Transcript of BIOS earnings conference call or presentation 4-May-17 1:00pm GMT Jun 26 2017
Why Is BioScrip (BIOS) Up 15.3% Since the Last Earnings Report? Jun 09 2017
Today's Research Reports on Stocks to Watch: Synergy Pharmaceuticals and Bioscrip Inc. Jun 05 2017
BioScrip Provides Update on UnitedHealthcare Contract May 30 2017
BioScrip to Present at the Jefferies 2017 Global Healthcare Conference May 24 2017
ETFs with exposure to BioScrip, Inc. : May 23, 2017 May 23 2017
Dull Q1 Earnings & Tough Industry Spell Trouble for BioScrip May 11 2017
BioScrip, Inc. :BIOS-US: Earnings Analysis: Q1, 2017 By the Numbers : May 9, 2017 May 09 2017
BioScrip (BIOS) Q1 Loss Narrower than Expected, Sales Miss May 05 2017
BioScrip reports 1Q loss May 04 2017
BioScrip Reports First Quarter 2017 Financial Results May 04 2017
Investor Network: BioScrip, Inc. to Host Earnings Call May 04 2017

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)

GF Chat

{{numOfNotice}}